We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 1/1/2022

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

featured

Journal Scan / Research · November 16, 2021

Third Dose Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

The Lancet

 

TAKE-HOME MESSAGE

abstract

This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Effectiveness of a Third Dose of the BNT162b2 mRNA COVID-19 Vaccine for Preventing Severe Outcomes in Israel: An Observational Study
Lancet 2021 Oct 29;[EPub Ahead of Print], Noam Barda, MD

Further Reading